JP7895334B2 - シクロデキストリンによるコレステロール結晶塞栓症の予防方法 - Google Patents

シクロデキストリンによるコレステロール結晶塞栓症の予防方法

Info

Publication number
JP7895334B2
JP7895334B2 JP2023513678A JP2023513678A JP7895334B2 JP 7895334 B2 JP7895334 B2 JP 7895334B2 JP 2023513678 A JP2023513678 A JP 2023513678A JP 2023513678 A JP2023513678 A JP 2023513678A JP 7895334 B2 JP7895334 B2 JP 7895334B2
Authority
JP
Japan
Prior art keywords
cyclodextrin
hydroxypropyl
individual
cholesterol crystals
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023513678A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543132A (ja
JP2023543132A5 (cg-RX-API-DMAC10.html
Inventor
カーウィン,ダイアナ
カム,ジェイソン
Original Assignee
ベレン セラピューティクス ピー.ビー.シー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベレン セラピューティクス ピー.ビー.シー. filed Critical ベレン セラピューティクス ピー.ビー.シー.
Publication of JP2023543132A publication Critical patent/JP2023543132A/ja
Publication of JP2023543132A5 publication Critical patent/JP2023543132A5/ja
Application granted granted Critical
Publication of JP7895334B2 publication Critical patent/JP7895334B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Steroid Compounds (AREA)
JP2023513678A 2020-08-27 2021-08-27 シクロデキストリンによるコレステロール結晶塞栓症の予防方法 Active JP7895334B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063071243P 2020-08-27 2020-08-27
US63/071,243 2020-08-27
PCT/US2021/048075 WO2022047244A1 (en) 2020-08-27 2021-08-27 Methods for the prevention of cholesterol crystal embolization with cyclodextrins

Publications (3)

Publication Number Publication Date
JP2023543132A JP2023543132A (ja) 2023-10-13
JP2023543132A5 JP2023543132A5 (cg-RX-API-DMAC10.html) 2024-08-27
JP7895334B2 true JP7895334B2 (ja) 2026-07-27

Family

ID=80352440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513678A Active JP7895334B2 (ja) 2020-08-27 2021-08-27 シクロデキストリンによるコレステロール結晶塞栓症の予防方法

Country Status (11)

Country Link
US (1) US20230302042A1 (cg-RX-API-DMAC10.html)
EP (1) EP4203973A4 (cg-RX-API-DMAC10.html)
JP (1) JP7895334B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230096976A (cg-RX-API-DMAC10.html)
CN (1) CN116635007A (cg-RX-API-DMAC10.html)
AU (1) AU2021331485A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023003490A2 (cg-RX-API-DMAC10.html)
CA (1) CA3190764A1 (cg-RX-API-DMAC10.html)
IL (1) IL300881A (cg-RX-API-DMAC10.html)
MX (1) MX2023002420A (cg-RX-API-DMAC10.html)
WO (1) WO2022047244A1 (cg-RX-API-DMAC10.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
WO2013155485A2 (en) * 2012-04-13 2013-10-17 Alessia Fornoni Method of using cyclodextrin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GREBE, A.,Targeting cholesterol crystals in atherosclerosis with cholesterol solubilizing 2-hydroxypropyl-β-cyclodextrin,2016年,pp.1-132,URL:https://d-nb.info/1124540296/34
The Journal of Biomedical Research,2017年,31(2),pp.82-94

Also Published As

Publication number Publication date
CA3190764A1 (en) 2022-03-03
CN116635007A (zh) 2023-08-22
WO2022047244A1 (en) 2022-03-03
MX2023002420A (es) 2023-07-11
JP2023543132A (ja) 2023-10-13
US20230302042A1 (en) 2023-09-28
EP4203973A4 (en) 2024-08-21
BR112023003490A2 (pt) 2023-05-09
AU2021331485A1 (en) 2023-03-23
EP4203973A1 (en) 2023-07-05
KR20230096976A (ko) 2023-06-30
IL300881A (en) 2023-04-01

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240819

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260616

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260714

R150 Certificate of patent or registration of utility model

Ref document number: 7895334

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150